Please assess the completion status of the following clinical trial:

Trial Title: Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with essential hypertension defined as having~   1. untreated, seated systolic blood pressure (SBP) of 130 mmHg or greater on three separate occasions, or~  2. untreated, seated diastolic BP (DBP) of 80 or greater on three separate occasions, or~  3. taken anti-hypertensive agent(s) for a minimum of six months.~2. For female subjects, the following conditions must be met:~   1. postmenopausal status for at least one year, or~  2. status post-surgical sterilization, or~  3. if of childbearing potential, utilization of adequate birth control and willingness to undergo urine beta-human chorionic gonadotropin (hCG) testing prior to drug treatment and on every study day.~Exclusion Criteria:~1. Presence of secondary form of hypertension~2. Symptomatic hypertension and/or SBP\>170 mmHg or DBP\>110 mmHg, relevant to the washout period~3. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, angiotensin-converting enzyme inhibitor (ACEi), ARBs, or NEPi, as well as known or suspected contraindications to the study drugs~4. History of angioedema~5. History of pancreatitis or known pancreatic lesions~6. History of significant cardiovascular disease (other than essential hypertension and left ventricular hypertrophy)~7. Symptomatic hypotension and/or a SBP\<100 mmHg at screening or \<95 mmHg during the study~8. Serum potassium \>5.2 mmol/L at screening or \>5.4 mmol/L during the study~9. Individuals using oral contraceptives and smokers in order to reduce the risk of thrombosis following arterial line placement~10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack within six months~11. Presence of significant pulmonary disorders~12. Type 1 diabetes~13. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c \>9%~14. Hematocrit \<35%~15. Impaired renal function \[estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73 m2\] as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years: eGFR (mL/min/1.73m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female)~16. Use of hormone-replacement therapy~17. Breast feeding and pregnancy~18. History or presence of immunological or hematological disorders~19. History of malignancy other than non-melanoma skin cancer~20. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week~21. Clinically significant gastrointestinal impairment that could interfere with drug absorption~22. Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \>3.0 x upper limit of normal range\]~23. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal anti-inflammatory drugs~24. Treatment with chronic systemic glucocorticoid therapy within the last year~25. Treatment with lithium salts~26. History of alcohol or drug abuse~27. Treatment with any investigational drug in the one month preceding the study~28. Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study~29. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- valsartan then LCZ696 (Type: ACTIVE_COMPARATOR): After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.
- LCZ696 then valsartan (Type: ACTIVE_COMPARATOR): After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.

Based on this trial design, predict the completion outcome and termination type (if applicable).